Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

A Prospective Clinical Study of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Double Expression Diffuse Large B-Cell Lymphoma

Yingying Wu, Ao Zhang, Liling Zhang, Guohui Cui, Fang Liu, Zhichao Chen, Zhipeng Chen, Lu Zhang, Lin Liu, Wenjuan He, Yu Hu, Linghui Xia, Jun Fang

Blood (2024) 144 (Supplement 1): 6501.

https://doi.org/10.1182/blood-2024-202483

Published: 2024

Journal Articles

BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial

Wenjing Luo, Yinqiang Zhang, Chenggong Li, Jia Xu, Wu Zhuolin, Xindi Wang, Yun Kang, Danying Liao, Haiming Kou, Wei Xie, Wei Xiong, Jun Deng, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 6546.

https://doi.org/10.1182/blood-2024-205304

Published: 2024

Journal Articles

A Retrospective Analysis of the Efficacy and Safety of Orelabrutinib-Containing Regimens in Marginal Zone Lymphoma

Hongyong Zhang, Zhipeng Cheng, Heng Mei, Chunyan Sun, Yingying Wu, Danying Liao, Fei Zhao, Yu Hu, Linghui Xia, Jun Fang

Blood (2024) 144 (Supplement 1): 6282.

https://doi.org/10.1182/blood-2024-198795

Published: 2024

Journal Articles

Gut Microbial Metabolite Butyrate Alleviates the Susceptibility to Septic DIC By Suppressing Caspase-11/ Gsdmd-Dependent Macrophage Pyroptosis

Yingying Li, Zhong Wu, Huiwen Jiang, Zhaozhao Chen, Min Xu, Jinhui Shu, Jingming Wang, Qinying Xie, Jun Deng, Yu Hu, Lili Luo, Heng Mei

Blood (2024) 144 (Supplement 1): 3993.

https://doi.org/10.1182/blood-2024-205102

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

In Situ Bioorthogonal Labeling for Non-Invasive, Dynamic In Vivo Nirf/PET Imaging of CAR-T Cells

Zhaozhao Chen, Anqi Ren, Hekuan Huang, Yingying Li, Jinhui Shu, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2024-209178

Published: 2024

Journal Articles

IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway

Yingying Li, Lili Luo, Jianghua Wu, Zhong Wu, Huiwen Jiang, Zhaozhao Chen, Jiachen Liu, Jinhui Shu, Jingming Wang, Min Xu, Mengyi Du, Jun Deng, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2024-202845

Published: 2024

Journal Articles

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Blood (2024) 144 (Supplement 1): 5.

https://doi.org/10.1182/blood-2024-199718

Published: 2024

Journal Articles

Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

Li Weiming, Yanli Zhang, Huanling Zhu, Yunfan Yang, Na Xu, Bingcheng Liu, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu

Blood (2024) 144 (Supplement 1): 480.

https://doi.org/10.1182/blood-2024-204996

Published: 2024

Journal Articles

The Impact and the Predictive Ability of Immunogenicity of Humanized Anti-CD19 CAR-T Cells for the Efficacy and Prognosis

Zhongpei Huang, Jia Xu, Chenggong Li, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 7142.

https://doi.org/10.1182/blood-2024-205047

Published: 2024

Journal Articles

Natural Killer-Cell Recovery in Patients Receiving CD19 CAR T-Cell Therapy: Dynamics and Clinical Significance

Xindi Wang, Wenjing Luo, Lu Tang, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 7217.

https://doi.org/10.1182/blood-2024-205259

Published: 2024

Journal Articles

Enhanced Risk of Cytokine Release Syndrome in Obese and Related Comorbidities Undergoing CAR-T Therapy for B-Cell Malignancies

Rosanna Tryphene Massounga Mayombo, Mengyi Du, Jiachen Liu, Yinqiang Zhang, Danying Liao, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 7216.

https://doi.org/10.1182/blood-2024-205054

Published: 2024

Journal Articles

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Blood (2024) 144 (Supplement 1): 4855.

https://doi.org/10.1182/blood-2024-202870

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

Journal Articles

DDX3X Promotes Multiple Myeloma Cell Survival and Proteasome Inhibitor Resistance through Modulation of Stress Granule Assembly and MAPKAPK2 Translation

Shijun Jiang, Fengjuan Fan, Klaus Podar, Chunyan Sun, Yu Hu

Blood (2024) 144 (Supplement 1): 4662.

https://doi.org/10.1182/blood-2024-209175

Published: 2024

Journal Articles

mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells

Zhaozhao Chen, Anqi Ren, Jinhui Shu, Yingying Li, Hekuan Huang, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 4847.

https://doi.org/10.1182/blood-2024-209037

Published: 2024

Journal Articles

Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma

Qun Li, Chi Ma, Liping Zuo, Aoshuang Xu, Fei Zhao, Yu Hu, Chunyan Sun

Blood (2024) 144 (Supplement 1): 4659.

https://doi.org/10.1182/blood-2024-201184

Published: 2024

Journal Articles

HIF-1α Agonist Ameliorates Acute Graft-Versus-Host Disease Via Restraining SIRT1/ PARP1 in Bone Marrow Endothelial Progenitor Cells

Xie-Na Cao, Wen-Kai Zhang, Wei Shi, Ling-Hui Xia, Li Li, Chun-Yan Sun, Yu Hu

Blood (2024) 144 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2024-204456

Published: 2024

Journal Articles

Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature

Xindi Wang, Wenjing Luo, Zhaozhao Chen, Yu Hu, Heng Mei

Blood (2024) 144 (Supplement 1): 4816.

https://doi.org/10.1182/blood-2024-205045

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

NARROW

A Prospective Clinical Study of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Double Expression Diffuse Large B-Cell Lymphoma

BTK Inhibitor Synergizes with CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients with Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial

A Retrospective Analysis of the Efficacy and Safety of Orelabrutinib-Containing Regimens in Marginal Zone Lymphoma

Gut Microbial Metabolite Butyrate Alleviates the Susceptibility to Septic DIC By Suppressing Caspase-11/ Gsdmd-Dependent Macrophage Pyroptosis

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

In Situ Bioorthogonal Labeling for Non-Invasive, Dynamic In Vivo Nirf/PET Imaging of CAR-T Cells

IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

The Impact and the Predictive Ability of Immunogenicity of Humanized Anti-CD19 CAR-T Cells for the Efficacy and Prognosis

Natural Killer-Cell Recovery in Patients Receiving CD19 CAR T-Cell Therapy: Dynamics and Clinical Significance

Enhanced Risk of Cytokine Release Syndrome in Obese and Related Comorbidities Undergoing CAR-T Therapy for B-Cell Malignancies

Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

DDX3X Promotes Multiple Myeloma Cell Survival and Proteasome Inhibitor Resistance through Modulation of Stress Granule Assembly and MAPKAPK2 Translation

mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells

Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma

HIF-1α Agonist Ameliorates Acute Graft-Versus-Host Disease Via Restraining SIRT1/ PARP1 in Bone Marrow Endothelial Progenitor Cells

Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only